hereditary angioedema

Hand with tweezers editing DNA
Biotech

Intellia races in vivo CRISPR therapy to FDA after phase 3 win

William Blair analysts called lonvo-z a “compelling one-time option" after seeing the phase 3 data.
Nick Paul Taylor Apr 27, 2026 9:24am
An arrow incrementally going up stairs before pointing straight up Blue background

Pharvaris clocks a pivotal win in race for rapid HAE relief

Dec 3, 2025 9:10am
Three blocks displaying from left to right a person a handshake and another person

BioCryst inks $700M Astria deal to rival Takeda in rare disease

Oct 14, 2025 10:30am
Two businessmen pushing giant puzzle pieces together as the sun sets behind them

Kaken strengthens late-stage HAE portfolio with $32M Astria deal

Aug 6, 2025 10:21am
FDA stop sign

FDA's 'heavy workload' blamed for delaying KalVista's PDUFA date

Jun 16, 2025 4:33am
Three blocks displaying from left to right a person a handshake and another person

KalVista sells Japanese rights for HAE drug to Kaken

Apr 8, 2025 8:35am